PT-141

Bremelanotide (Vyleesi)

PT-141 is the only FDA-approved peptide that targets desire at the neurological level. Viagra works on plumbing. PT-141 activates melanocortin-4 receptors in your brain to increase actual want. It's approved as Vyleesi for women with low desire, but the community uses it across genders. The nausea at the full FDA dose (1.75mg) is significant — 40% in trials. Most people start at 500mcg and find their spot between there and 1mg. Takes about 45-60 minutes to kick in.

Protocol

Dose: 500mcg-1.75mg per use | Frequency: As needed, at least 45 minutes before activity. Max 1 dose per 24 hours, max 8 doses per month (FDA guidance). | Cycle: As needed (not cycled) | Route: SubQ

Reconstitution: 2mL bacteriostatic water per 10mg vial. Use our free reconstitution calculator for exact syringe units.

Effects

• Increased sexual desire (65%) — Works on the brain's desire circuitry, not mechanics — users describe feeling genuinely interested rather than just physically responsive
• Enhanced arousal (58%) — Both physical arousal and psychological arousal improve, which is the key differentiator from PDE5 inhibitors
• Skin flushing / warmth (45%) — A warm flush across the face and body within 30-60 minutes of injection — not a side effect for everyone, some consider it part of the experience
• Improved satisfaction (50%) — Higher overall satisfaction scores reported in clinical trials

Side Effects

• Nausea (40%) — The big trade-off. 40% at the full dose. Starting at 500mcg instead of 1.75mg cuts this dramatically.
• Flushing (20%) — Warm flush across your face, neck, and chest. Can be intense. Some people kind of like it, honestly.
• Injection-site reactions (13%) — Red mark or mild soreness where you pinned. Standard.
• Headache (11%) — Mild to moderate headache. Showed up in trials. Tends to pass.
• Hyperpigmentation (1%) — Rare but documented — skin darkening on face, gums, or breasts. Usually goes back to normal when you stop.

Evidence

Strong evidence — FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Works through the central nervous system via melanocortin receptors — fundamentally different from Viagra, which is about blood flow. The RECONNECT trials showed statistically significant improvement in sexual desire. Nausea is the main trade-off.

Approval status: FDA-approved (branded)

References

1. Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist J Sex Med, 2006. PMID: 16839319
2. Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials Obstet Gynecol, 2019. PMID: 31599840
3. Simon JA et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder Obstet Gynecol, 2019. PMID: 31599847
4. Mayer D et al. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder Ann Pharmacother, 2020. PMID: 31893927
5. Koochaki P et al. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results J Womens Health (Larchmt), 2021. PMID: 33538638
6. Simon JA et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide J Womens Health (Larchmt), 2022. PMID: 35230162

Storage

• Lyophilized: Refrigerate at 2-8C. Stable for 12+ months sealed.
• Reconstituted: Refrigerate. Use within 4-6 weeks.
• Water: Bacteriostatic water, 2mL per 10mg vial.
• Needle: 29-31 gauge, 0.5 inch for subcutaneous injection in abdomen or thigh

← Browse all peptides | Dose calculator →

These statements have not been evaluated by the FDA. This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any protocol.

vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify